SuperworthTandem Diabetes Care profit margin TNDM
Gross, operating and net profit as a share of revenue over the last twelve months, from 2015.
- Net margin, 12 months
- −6.1%
- Operating margin, 12 months
- −4.4%
- Net margin on a year earlier
- +14.4 pts
- Peer median
- 7.7%
Over the twelve months to Jun 30, 2026, Tandem Diabetes Care kept −6.1% of its revenue as net profit, with an operating margin of −4.4% and a gross margin of 56.0%.
Five years earlier its net margin was 1.1%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −20.2% | −18.5% | 53.8% |
| FY2024 | −10.2% | −10.5% | 52.1% |
| FY2023 | −29.8% | −31.2% | 49.2% |
| FY2022 | −11.8% | −11.6% | 51.5% |
| FY2021 | 2.2% | 3.2% | 53.5% |
| FY2020 | −6.9% | −1.6% | 52.2% |
| FY2019 | −6.8% | −4.6% | 53.6% |
| FY2018 | −66.7% | −24.3% | 48.9% |
| FY2017 | −67.9% | −58.5% | 41.0% |
| FY2016 | −99.1% | −92.6% | 28.0% |
| FY2015 | −99.4% | −94.7% | 36.5% |
| FY2014 | n/a | n/a | 30.7% |
| FY2013 | n/a | n/a | 21.3% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −6.1% | +14.4 pts | −4.4% | |
| Q1 FY26 | −9.2% | +9.5 pts | −8.2% | |
| Q4 FY25 | −20.2% | −10.0 pts | −18.5% | |
| Q3 FY25 | −20.2% | −5.4 pts | −19.5% | |
| Q2 FY25 | −20.5% | −3.4 pts | −19.9% | |
| Q1 FY25 | −18.7% | −0.3 pts | −18.1% | |
| Q4 FY24 | −10.2% | +19.6 pts | −10.5% | |
| Q3 FY24 | −14.8% | +12.2 pts | −15.6% | |
| Q2 FY24 | −17.1% | +11.3 pts | −17.5% | |
| Q1 FY24 | −18.4% | +7.3 pts | −19.1% | |
| Q4 FY23 | −29.8% | −18.0 pts | −31.2% | |
| Q3 FY23 | −27.0% | −18.4 pts | −28.0% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Tandem Diabetes Care's size, closest first, today.
| Company | Profit margin |
|---|---|
| TNDMTandem Diabetes Care | −6.1% |
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| STAAStaar Surgical | 1.1% |
| IRMDIradimed | 26.7% |
| EYENational Vision | 2.5% |
| LMATLemaitre Vascular | 25.0% |
| INSPInspire Medical Systems | 15.0% |
| MOVMovado | 6.0% |
| UFPTUFP Technologies | 11.4% |
| MDXGMimedx | 1.8% |
| Peer median | 7.7% |
Where Tandem Diabetes Care ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Tandem Diabetes Care
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.